Melinta Therapeutics

Melinta Therapeutics, Inc. is a commercial-stage pharmaceutical company based in Morristown, New Jersey, specializing in the discovery, development, and commercialization of anti-infective therapies for bacterial infections in North America. The company offers several antibiotics, including Baxdela for acute bacterial skin and skin structure infections, Vabomere for gram-negative infections, Orbactiv, also for skin infections, and Minocin, which targets both gram-positive and gram-negative pathogens. Melinta is actively developing delafloxacin, an investigational antibiotic currently in Phase 3 trials for acute bacterial skin and skin structure infections. Additionally, the company is engaged in research aimed at creating a new class of antibiotics to combat drug-resistant ESKAPE pathogens, which are responsible for many serious hospital infections. Melinta’s mission is to address the urgent need for innovative antibiotics to tackle the growing problem of drug-resistant infections, a significant public health challenge.